For the moment, it is known that it is an anti-inflammatory commensal stimulating the secretion of IL-10 and inhibiting the expression of IL-12 and interferon-γ and that it is reduced in many of the NAFLD patients, reduced due to the “NAFLD-signature,” which is a particular profile representing the various intestinal microbial species, characterized by an increase in the levels of bacteria and a reduction in the levels of bacteria, typical of NAFLD patients and non-healthy ones (Grabherr et al., 2019). The gene discussed is IL10; the disease is metabolic dysfunction-associated steatotic liver disease.